TP53 and post-traumatic stress disorder: Lastly, based on the more qualitative nature of the MeDIPseq results showing hypermethylation of the TP53 promoter in PTSD patients compared to controls in the current report, ample justification is now provided to examine this observation in a more quantitative assay (e.g. methylation-specific PCR, or MSP) in a larger human subject cohort.